THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
The clinical significance of CYP2C19 genetic polymorphism, associated with the violation of the formation of the active clopidogrel metabolite, for efficacy and safety of this drug in cardiology practice is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 test...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | http://www.rpcardio.ru/jour/article/view/99 |
| _version_ | 1797714444346720256 |
|---|---|
| author | K. B. Mirzaev D. A. Sychev D. A. Andreev A. B. Prokofiev |
| author_facet | K. B. Mirzaev D. A. Sychev D. A. Andreev A. B. Prokofiev |
| author_sort | K. B. Mirzaev |
| collection | DOAJ |
| description | The clinical significance of CYP2C19 genetic polymorphism, associated with the violation of the formation of the active clopidogrel metabolite, for efficacy and safety of this drug in cardiology practice is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 testing, as well as the indications for this approach use in clinical practice are presented. Consideration of these testing results should increase the efficacy and safety of antiplatelet treatment. |
| first_indexed | 2024-03-12T07:52:04Z |
| format | Article |
| id | doaj.art-b0b1f96746f64689bb5be45ad5642074 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-03-12T07:52:04Z |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-b0b1f96746f64689bb5be45ad56420742023-09-02T20:32:12ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-019440440810.1234/1819-6446-2013-4-404-40898THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICEK. B. Mirzaev0D. A. Sychev1D. A. Andreev2A. B. Prokofiev3Первый Московский медицинский университет имени И.М. Сеченова, МоскваПервый Московский медицинский университет имени И.М. Сеченова, Центр клинической фармакологии Научного центра экспертизы средств медицинского применения Минздрава России, МоскваПервый Московский медицинский университет имени И.М. Сеченова, МоскваПервый Московский медицинский университет имени И.М. Сеченова, Центр клинической фармакологии Научного центра экспертизы средств медицинского применения Минздрава России, МоскваThe clinical significance of CYP2C19 genetic polymorphism, associated with the violation of the formation of the active clopidogrel metabolite, for efficacy and safety of this drug in cardiology practice is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 testing, as well as the indications for this approach use in clinical practice are presented. Consideration of these testing results should increase the efficacy and safety of antiplatelet treatment.http://www.rpcardio.ru/jour/article/view/99резистентность к клопидогрелуфармакогенетикаCYP2С19 |
| spellingShingle | K. B. Mirzaev D. A. Sychev D. A. Andreev A. B. Prokofiev THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE Рациональная фармакотерапия в кардиологии резистентность к клопидогрелу фармакогенетика CYP2С19 |
| title | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE |
| title_full | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE |
| title_fullStr | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE |
| title_full_unstemmed | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE |
| title_short | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE |
| title_sort | significance of pharmacogenetic cyp2c19 testing for personalization of the antiplatelet therapy in cardiology practice |
| topic | резистентность к клопидогрелу фармакогенетика CYP2С19 |
| url | http://www.rpcardio.ru/jour/article/view/99 |
| work_keys_str_mv | AT kbmirzaev thesignificanceofpharmacogeneticcyp2c19testingforpersonalizationoftheantiplatelettherapyincardiologypractice AT dasychev thesignificanceofpharmacogeneticcyp2c19testingforpersonalizationoftheantiplatelettherapyincardiologypractice AT daandreev thesignificanceofpharmacogeneticcyp2c19testingforpersonalizationoftheantiplatelettherapyincardiologypractice AT abprokofiev thesignificanceofpharmacogeneticcyp2c19testingforpersonalizationoftheantiplatelettherapyincardiologypractice AT kbmirzaev significanceofpharmacogeneticcyp2c19testingforpersonalizationoftheantiplatelettherapyincardiologypractice AT dasychev significanceofpharmacogeneticcyp2c19testingforpersonalizationoftheantiplatelettherapyincardiologypractice AT daandreev significanceofpharmacogeneticcyp2c19testingforpersonalizationoftheantiplatelettherapyincardiologypractice AT abprokofiev significanceofpharmacogeneticcyp2c19testingforpersonalizationoftheantiplatelettherapyincardiologypractice |